Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2020, Vol. 47 Issue (2): 174-178    DOI: 10.31083/j.ceog.2020.02.5014
Original Research Previous articles | Next articles
Clinical analysis of atrial fibrillation in pregnant women
H. F. Zhang1, J. Zhang1, D. Yang1, *(), S. N. Li2
1Obstetrics and Gynecology Medical Centre of Severe Cardiovascular Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China
2Department of Cardiology, Beijing Anzhen Hospital, Beijing 100029, P.R. China
Download:  PDF(494KB)  ( 247 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  Objective: To analyze the clinical characteristics and risk factors for the major adverse cardiovascular events (MACEs) of atrial fibrillation (AF) in pregnant women. Materials and Methods: A retrospective analysis was performed on 35 pregnant women with AF, who were treated at Beijing Anzhen Hospital, Capital Medical University, from January 2004 to May 2017. All pregnancies were recorded. Chi-squared test analysis was performed to determine the correlation between clinical factors and MACEs. Results: There were 11 cases of MACEs (31.4%), including 10 cases of heart failure (HF) and 1 case of cerebral infarction. We found 7 clinical factors with a clear correlation with the occurrence of MACEs during pregnancy: a medical history of heart operation (P = 0.0011) and AF before pregnancy (P = 0.0281), New York Heart Association (NYHA) class (P < 0.0001), a left ventricular ejection fraction (LVEF) ≤ 50% (P = 0.0055), and a delivery time < 37 weeks (P = 0.0037). The AF subtype and delivery mode have no correlation with MACEs. Conclusion: AF in pregnant women is dangerous for pregnancy and delivery, multi-disciplinary management of obstetricians, cardiologists, and neonatologists are crucial for these patients throughout pregnancy.
Key words:  Atrial fibrillation      Pregnancy      Clinical factors      MACEs     
Published:  15 April 2020     
*Corresponding Author(s):  D. Yang     E-mail:  cndongyang@126.com

Cite this article: 

H. F. Zhang, J. Zhang, D. Yang, S. N. Li. Clinical analysis of atrial fibrillation in pregnant women. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 174-178.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2020.02.5014     OR     https://ceog.imrpress.com/EN/Y2020/V47/I2/174

Table 1  — Classification of pregnant women with AF.
Subtypes of AF N (%)
I: Lone atrial fibrillation (LAF) 8 (22.8%)
II: Secondary to structural heart disease 24 (68.6%)
AF in CHD 2
AF in RHD 19
AF in Cardiomyopathy 3
III: No structural heart disease 3 (8.6%)
Hypertension atrial fibrillation 1
Hyperthyroid atrial fibrillation 1
Hypothyroid atrial fibrillation 1
Table 2  — Maternal baseline characteristics.
Characteristics N (%)
Age (years)
<35 29 (82.9%)
≥35 6 (17.1%)
Multipara
Yes 6 (17.1%)
No 29 (82.9%)
NYHA class
I-II 24 (68.6%)
III-IV 11 (31.4%)
LVEF
≤40% 9 (25.7%)
41-54% 5 (14.3%)
≥55% 21 (60.0%)
AF medical history
Yes 22 (62.9%)
No 13 (37.1%)
Symptom
Symptomatic AF 24 (68.6%)
Asymptomatic AF 11 (31.4%)
Medical history
AF 22 (62.9%)
Heart failure 0 (0%)
Hypertension 1 (2.9%)
Cerebral infarction 1 (2.9%)
Operation for heart disease pre-pregnancy 13 (37.1%)
Table 3  — Pregnancy outcomes of pregnant women with AF.
Characteristics N (%)
Delivery week
≤28 3 (8.6%)
28-32 (32) 3 (8.6%)
32-36 (36) 10 (28.6%)
≥37 19 (54.3%)
Delivery mode
Vaginal 7 (20.0%)
Cesarean section 28 (80.0%)
Obstetrical complication
PROM 2 (5.7%)
Preeclampsia 4 (11.4%)
GDM 2 (5.7%)
Postpartum hemorrhage 1 (2.9%)
Neonatal outcome
Birth time
Full-term 19 (54.3%)
Premature 13 (37.1%)
Medical induced abortion 3 (8.6%)
Birth-weight
Normal 20 (57.1%)
Low 12 (34.3%)
NA 3 (8.6%)
Neonatal asphyxia
Yes 5 (14.3%)
No 27 (77.1%)
Table 4  — Characteristics of patients who have experienced MACEs in this study.
Structural-heart disease MACEs NYHA class LVEF (%) AF Heart operation before pregnancy
RHD HF I-II 55 Y Y
Cardiomyopathy (PPCM) HF III-IV 20 N N
RHD HF III-IV 48 N N
RHD HF III-IV 40 Y N
RHD HF III-IV 44 N N
RHD HF III-IV 40 N N
RHD HF III-IV 33 N N
Cardiomyopathy (DCM) HF III-IV 40 N N
Cardiomyopathy (RCM) Cerebral infarction III-IV 55 N N
RHD HF III-IV 50 Y N
No HF I-II 50 Y NA
Table 5  — Comparison of clinical factors between patients with and without Major Adverse Cardiovascular Events (MACEs) during pregnancy and postpartum period.
Clinical factors MACEs (n = 11) No MACEs (n = 26) P -value (Chi-square)
Subtype 0.1443 (3.8723)
I 1 (12.5%) 7 (87.5%)
II 10 (41.67%) 14 (58.33%)
III 0 3
Medical history of heart operation 0.0011 (10.5926)
After Heart operation 1 (7.69%) 12 (92.31%)
No Heart operation 9 (81.82%) 2 (18.18%)
NA 1 10
NYHA class
I-II

2 (8.33%)

22 (91.6%)
< 0.0001 (18.9001)
III-IV 9 (81.82%) 2 (18.18%)
Medical history of AF 0.0281 (4.8228)
Yes 4 (18.18%) 18 (81.82%)
No 7 (53.85%) 6 (46.15%)
LVEF% 0.0055 (7.7215)
50
>50
7 (63.64%)
4 (16.67%)
4 (36.36%)
20 (83.33%)
Delivery time 0.0037 (8.4260)
<37 weeks 9 (56.25%) 7 (43.75%)
37week 2 (10.53%) 17 (89.47%)
Delivery mode 0.1218* (2.3946)
Vaginal 0 7 (100%)
Cesarean section 11 (39.29%) 17 (60.71%)
[1] Hu Y.F., Chen Y.J., Lin Y.J., Chen S.A.: “Inflammation and the pathogenesis of atrial fibrillation”. Nat. Rev. Cardiol., 2015, 12, 230.
doi: 10.1038/nrcardio.2015.2 pmid: 25622848
[2] Lee M.S., Chen W., Zhang Z., Duan L., Ng A., Spencer H.T., et al.: “Atrial Fibrillation and Atrial Flutter in Pregnant Women-A Population-Based Study”. J. Am. Heart Assoc., 2016, 5, e003182.
doi: 10.1161/JAHA.115.003182 pmid: 27076563
[3] Altun B., Tasolar H., Gazï E., Gungor A.C., Uysal A., Temïz A., et al.: “Atrial electromechanical coupling intervals in pregnant subjects”. Cardiovasc. J. Afr., 2014, 25, 15.
doi: 10.5830/CVJA-2013-085
[4] Thihalolipavan S., Morin D.P.: “Atrial fibrillation and heart failure: update 2015”. Prog. Cardiovasc. Dis., 2015, 58, 126.
doi: 10.1016/j.pcad.2015.07.004 pmid: 26192885
[5] January C.T., Wann L.S., Alpert J.S., Calkins H., Cigarroa J.E., Cleveland J.C. J., et al.: “2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American. College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society”. J. Am. Coll. Cardiol., 2014, 64, e1.
doi: 10.1016/j.jacc.2014.03.022 pmid: 24685669
[6] Bessissow A., Khan J., Devereaux P.J., Alvarez-Garcia J., Alonso-Coello P.: “Postoperative atrial fibrillation in non-cardiac and cardiac surgery: an overview”. J. Thromb. Haemost., 2015, 13, S304.
doi: 10.1111/jth.12974 pmid: 26149040
[7] Salam A.M., Ertekin E., van Hagen I.M., Al Suwaidi J., Ruys T.P.E., Johnson M.R., et al.: “Atrial Fibrillation or Flutter during Pregnancy in Patients with Structural Heart Disease: data from the ROPAC”. JACC Clin. Electrophysiol., 2015, 1, 284.
[8] Trappe H.J.: “Acute therapy of maternal and fetal arrhythmias during pregnancy”. J. Intensive Care Med., 2006, 21, 305.
doi: 10.1177/0885066606291433 pmid: 16946446
[9] Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., et al.: “2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS”. Eur. Heart J., 2016, 37, 2893.
doi: 10.1093/eurheartj/ehw210 pmid: 27567408
[10] Cacciotti L., Passaseo I.: “Management of Atrial Fibrillation in Pregnancy”. J. Atr. Fibrillation, 2010, 3, 295.
doi: 10.4022/jafib.295 pmid: 28496671
[11] Katsi V., Georgiopoulos G., Marketou M., Oikonomou D., Parthenakis F., Makris T., et al.: “Atrial fibrillation in pregnancy: a growing challenge”. Curr. Med. Res. Opin., 2017, 33, 1497.
doi: 10.1080/03007995.2017.1330257 pmid: 28498066
[12] Cho F.N.: “Management of pregnant women with cardiac diseases at potential risk of thromboembolism-experience and review”. Int. J. Cardiol., 2009, 136, 229.
doi: 10.1016/j.ijcard.2008.04.037 pmid: 18632171
[13] Wadke R.: “Atrial fibrillation”. Dis. Mon., 2013, 59, 67.
doi: 10.1016/j.disamonth.2012.12.002 pmid: 23410667
[14] Johnson M.J., Bland J.M., Davidson P.M., Newton P.J., Oxberry S.G., Abernethy A.P., et al.: “The relationship between two performance scales: New York Heart Association Classification and Karnofsky Performance Status Scale”. J. Pain. Symptom Manage., 2014, 47, 652.
doi: 10.1016/j.jpainsymman.2013.05.006 pmid: 23910628
[15] Ouzounian J.G., Elkayam U.: “Physiologic changes during normal pregnancy and delivery”. Cardiol. Clin., 2012, 30, 317.
doi: 10.1016/j.ccl.2012.05.004
[16] Chapman A.C., Cipolla M.J., Chan S.L.: “Effect of pregnancy and nitric oxide on the myogenic vasodilation of posterior cerebral arteries and the lower limit of cerebral blood flow autoregulation”. Reprod. Sci., 2013, 20, 1046.
doi: 10.1177/1933719112473661
[17] Joglar J.A., Page R.L.: “Management of arrhythmia syndromes during pregnancy”. Curr. Opin. Cardiol., 2014, 29, 36.
doi: 10.1097/HCO.0000000000000020
[18] Sengheiser C.J., Channer K.C.: “Recurrent atrial flutter and fibrillation in pregnancy”. BMJ Case Rep., 2011, 2011.
doi: 10.1136/bcr.07.2010.3156 pmid: 22715267
[19] Knotts R.J., Garan H.: “Cardiac arrhythmias in pregnancy”. Semin. Perinatol., 2014, 38, 285.
doi: 10.1053/j.semperi.2014.04.017
[20] Wolbrette D. : “Treatment of arrhythmias during pregnancy”. Curr. Womens Health Rep., 2003, 3, 135.
pmid: 12628083
[21] Anugu V.R., Nalluri N., Asti D., Gaddam S., Vazzana T., Lafferty J.: “New-onset lone atrial fibrillation in pregnancy”. Ther. Adv. Cardiovasc. Dis., 2016, 10, 274.
doi: 10.1177/1753944716644584 pmid: 27099243
[22] White S., Welch J., Brown L.H.: “The unexpected pitter patter: new-onset atrial fibrillation in pregnancy”. Case Rep. Emerg. Med., 2015, 2015, 318645.
doi: 10.1155/2015/318645 pmid: 25960893
[23] Kotecha D., Piccini J.P.: “Atrial fibrillation in heart failure: what should we do”? Eur. Heart J., 2015, 36, 3250.
doi: 10.1093/eurheartj/ehv513 pmid: 26419625
[24] DiCarlo-Meacham A., Dahlke J.: “Atrial fibrillation in pregnancy”. Obstet. Gynecol., 2011, 117, 489.
doi: 10.1097/AOG.0b013e31820561ef pmid: 21252800
[25] O’Brien E.C., Holmes D.N., Ansell J.E., Allen L.A., Hylek E., Kowey P.R., et al.: “Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry”. Am. Heart J., 2014, 167, 601.
doi: 10.1016/j.ahj.2013.12.014
[26] Goland S., Elkayam U. : “Anticoagulation in pregnancy”. Cardiol. Clin., 2012, 30, 395.
doi: 10.1016/j.ccl.2012.05.003
[1] Ali S. Alqahtani. Seroprevalence of Dengue virus among pregnant mothers and their-newborn infants in the southwest of Saudi Arabia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 741-743.
[2] M. Elmahdy, I. Elfourtia, H. Maghraby. Office hysteroscopy in cases of recurrent implantation failure; Do or not to do[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 723-728.
[3] L.L. Xu, J.Q. Li, Y.Q. Pu, C. Zhou, S.W. Feng, Q. Luo. Effect of prenatal depression during late pregnancy on maternal and neonatal outcomes[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 681-686.
[4] Y.X. Wang, M. Zhong, H. Yi, H.F. He. Detection of group B streptococcus colonization in cervical and lower vaginal secretions of pregnant women[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 669-674.
[5] I.F. Urunsak, U.K. Gulec, E. Eser, M. Sucu, C. Akcabay, S. Buyukkurt. The role of dinoprostone for labor induction in postterm and high-risk term pregnancies[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 664-668.
[6] S. Han, S. Choi, S. Nah, Y.H. Lee. Preterm labor in mild carbon monoxide poisoning: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 805-806.
[7] H.S.O. Abduljabbar, H. Abduljabar. A systematic review and meta-analysis of the reported symptoms of Covid 19 in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 632-637.
[8] M. Varras, C. Loukas, N. Nikiteas, V.K. Varra, F.N. Varra, E. Georgiou. Comparison of laparoscopic surgical skills acquired on a virtual reality simulator and a box trainer: an analysis for obstetrics-gynecology residents[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 755-763.
[9] H. Yolli, M.E. Demir, R. Yildizhan. Neutrophil gelatinase associated lipocalin-2 (Ngal) levels in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 519-523.
[10] K. Chikazawa, K. Imai, T. Kuwata, K. Takagi. Prophylactic laparoscopic adnexal surgery with low-pressure CO2 insufflation for ovarian cysts during the late first trimester or second trimester of pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 537-540.
[11] J. A. Villarreal-Rodriguez, L. G. Mancillas Adame, J. Maldonado-Sanchez, A. Guzmán-López, O. R. Treviño-Montemayor, J. G. Gonzalez-Gonzalez, D. Saldívar-Rodríguez. A randomized controlled trial comparing acarbose vs. insulin therapy for gestational diabetes in individuals with inadequate glycemic control by diet alone[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 552-555.
[12] J. Ogawa, S. Suzuki. Risk factors of self-interruption of medications for mental disorders in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 576-578.
[13] A. Daniilidis, G. Dryllis, G. Chorozoglou, M. Politou, R. Dampali, K. Dinas. Substitution of hemoglobin levels in pregnant women with iron supplement: A prospective randomized clinical study[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 579-583.
[14] Z.Y. Chang, R. Cao, R.C. Xu, Y. Cheng, Q.J. Wan. Pregnancy in a peritoneal dialysis patient undergoing intermittent peritoneal dialysis during the third trimester of pregnancy: a case report and literature review[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 596-599.
[15] C.Y. Huang, T.C. Chao, H.C. Chien, Y.L. Liu. Outcome of shared decision-making in a patient with primary herpes gingivostomatitis during pregnancy: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 604-606.
No Suggested Reading articles found!